Kristi L. Helke

Kristi L. Helke

Auto-generated profile, based on publicly available information

Kristi L. Helke

Department of Comparative Medicine, Medical University of South Carolina, Charleston, SC, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Cell Metabolism
Verified
Journal Article
Closed access
SCShilpak Chatterjee
Shilpak Chatterjee
ADAnusara Daenthanasanmak
Anusara Daenthanasanmak
PCParamita Chakraborty
Paramita Chakraborty
MWMegan W. Wyatt
Megan W. Wyatt
PDPayal Dhar
Payal Dhar
Shikhar MehrotraShikhar Mehrotra
Shikhar Mehrotra

26 May 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
JGJustin Goodwin
Justin Goodwin
MNMichael L. Neugent
Michael L. Neugent
SLShin Yup Lee
Shin Yup Lee
Joshua ChoeJoshua Choe
Joshua Choe
HCHyunsung Choi
Hyunsung Choi
JKJung-whan Kim
Jung-whan Kim
Adenocarcinoma (ADC) and squamous cell carcinoma (SqCC) are the two predominant subtypes of non-small cell lung cancer (NSCLC) and are distinct in their histological, molecular and clinical presentation. However, metabolic signatures specific to individual NSCLC subtypes remain unknown. Here, we perform an integrative analysis of human NSCLC tumour samples, patient-derived xenografts, murine model of NSCLC, NSCLC cell lines and The Cancer Genome Atlas (TCGA) and reveal a markedly elevated expression of the GLUT1 glucose transporter in lung SqCC, which augments glucose uptake and glycolytic flux. We show that a critical reliance on glycolysis renders lung SqCC vulnerable to glycolytic inhibition, while lung ADC exhibits significant glucose independence. Clinically, elevated GLUT1-mediated glycolysis in lung SqCC strongly correlates with high 18F-FDG uptake and poor prognosis. This previously undescribed metabolic heterogeneity of NSCLC subtypes implicates significant potential for the development of diagnostic, prognostic and targeted therapeutic strategies for lung SqCC, a cancer for which existing therapeutic options are clinically insufficient.

1 November 2017 in Brain Stimulation
Verified
Journal Article
Closed access
AFAriana Q. Farrand
Ariana Q. Farrand
KHKristi L. Helke
Kristi L. Helke
RGRebecca A. Gregory
Rebecca A. Gregory
MGMonika Gooz
Monika Gooz
VHVanessa K. Hinson
Vanessa K. Hinson
HBHeather A. Boger
Heather A. Boger

8 November 2012 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
KHKristi L Helke
Kristi L Helke
MSMarvin Michael Swindle
Marvin Michael Swindle
Introduction: In regulatory toxicological testing, both a rodent and non-rodent species are required. Historically, dogs and non-human primates (NHP) have been the species of choice of the non-rodent portion of testing. The pig is an appropriate option for these tests based on metabolic pathways utilized in xenobiotic biotransformation. Areas covered: This review focuses on the Phase I and Phase II biotransformation pathways in humans and pigs and highlights the similarities and differences of these models. This is a growing field and references are sparse. Numerous breeds of pigs are discussed along with specific breed differences in these enzymes that are known. While much available data are presented, it is grossly incomplete and sometimes contradictory based on methods used. Expert opinion: There is no ideal species to use in toxicology. The use of dogs and NHP in xenobiotic testing continues to be the norm. Pigs present a viable and perhaps more reliable model of non-rodent testing.

7 August 2017 in Oncogene
Verified
Journal Article
Open access
PDF file
MWM Wada
M Wada
DCD Canals
D Canals
MAM Adada
M Adada
NCN Coant
N Coant
MSMohamed Salama
Mohamed Salama
YHYusuf Hannun
Yusuf Hannun
The protein p38 mitogen-activated protein kinase (MAPK) delta isoform (p38δ) is a poorly studied member of the MAPK family. Data analysis from The Cancer Genome Atlas database revealed that p38δ is highly expressed in all types of human breast cancers. Using a human breast cancer tissue array, we confirmed elevation in cancer tissue. The breast cancer mouse model, MMTV-PyMT (PyMT), developed breast tumors with lung metastasis; however, mice deleted in p38δ (PyMT/p38δ−/−) exhibited delayed primary tumor formation and highly reduced lung metastatic burden. At the cellular level, we demonstrate that targeting of p38δ in breast cancer cells, MCF-7 and MDA-MB-231 resulted in a reduced rate of cell proliferation. In addition, cells lacking p38δ also displayed an increased cell–matrix adhesion and reduced cell detachment. This effect on cell adhesion was molecularly supported by the regulation of the focal adhesion kinase by p38δ in the human breast cell lines. These studies define a previously unappreciated role for p38δ in breast cancer development and evolution by regulating tumor growth and altering metastatic properties. This study proposes MAPK p38δ protein as a key factor in breast cancer. Lack of p38δ resulted in reduced primary tumor size and blocked the metastatic potential to the lungs.

1 September 2006 in Tuberculosis
Verified
Journal Article
Closed access
KHKris L. Helke
Kris L. Helke
JMJoseph L. Mankowski
Joseph L. Mankowski
YMYukari C. Manabe
Yukari C. Manabe